Abstract Library

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4449 Treatment of MiNEN with peptide receptor radionuclide therapy

Introduction: Mixed non-neuroendocrine and neuroendocrine neoplasms (MiNENs) of gastrointestinal tract are rare tumours with characteristic histological features include at least 30% of both neuroendocrine and non-neuroendocrine components of the whole neoplasm. They are usually treated with surgical resection and chemotherapy in advanced disease. However, there is scarcity of data for the use of peptide receptor radionuclide therapy (PRRT) in these tumours.

Conference:

Presenting Author: Shekhda K

Authors: Shekhda K, Luong T, Paterson A, Navalkissoor S, Krell D,

Keywords: MiNEN, PRRT, DOTATATE,

#4426 A case of giant neuroendocrine tumour of unknown primary site

Introduction: The liver is a common site for metastatic neuroendocrine tumours. NETs primary to the liver are rare, and it is difficult to determine whether a neuroendocrine tumour in the liver is primary or metastatic in patients in whom no tumour has been found elsewhere.

Conference:

Presenting Author: Yingmei T

Authors: Jieting D, Yanping Z, Yingmei T, Rongfang T, Yan W,

Keywords: neuroendocrine tumour, primary hepatic neuroendocrine tumour, metastatic,

#4422 A case report of an undifferentiated neuroendocrine carcinoma with an unknown primary site

Introduction: In the situation where the primary lesion remains unknown, high-grade poorly differentiated neuroendocrine carcinoma typically shows extensive metastasis at the time of clinical visit. Common metastatic sites include the liver, bones, lungs and brain, and the prognosis is extremely poor.

Conference:

Presenting Author:

Authors: Lv J, Tang Y,

Keywords: poorly differentiated neuroendocrine carcinoma, unknown primary origin,

#4389 The LOLA trial: Phase II trial with combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumours (NETs) – Interim results of step 1

Introduction: LOLA is an Italian, multicentre, open-label, double cohort, non-randomised, 3-stage, phase 2 trial aiming to assess the safety and activity of the combination of cabozantinib (CABO) + lanreotide (LAN) in patients (pts) with advanced or metastatic GEP and unknown primary NETs with Ki-67 > 10% or thoracic NET. In NETs sunitinib is the only TKI approved in advanced pancreatic NETs. While CABO has been reported superior to sunitinib in renal cancer its role in NETs is still investigational.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Brizzi M, Giuffrida D, Panzuto F,

Keywords: gastroenteropancreatic neuroendocrine tumour, cabozantinib, lanreotide, clinical trial,